Literature DB >> 8183243

Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.

F A Fornari1, J K Randolph, J C Yalowich, M K Ritke, D A Gewirtz.   

Abstract

The capacity of doxorubicin to inhibit topoisomerase II in the MCF-7 breast tumor cell line is supported by the induction of protein-associated single-strand breaks in DNA, as well as by interference with the decatenation activity of nuclear extracts. Doxorubicin also produces non-protein-associated DNA strand breaks (at a supraclinical concentration of 5 microM), which may indicate damage mediated via the generation of free radicals. However, no strand breaks are detected in DNA of MCF-7 cells at the IC50 for doxorubicin (approximately 0.1 microM). At doxorubicin concentrations of 0.05, 0.1, and 0.5 microM, at which growth is inhibited by approximately 15, 50, and 75%, respectively, doxorubicin interferes with radiation-induced unwinding of DNA; doxorubicin also produces a concentration-dependent inhibition of DNA synthesis that corresponds closely to growth inhibition. These studies suggest that DNA strand breaks fail to fully account for the antiproliferative activity of doxorubicin in the MCF-7 breast tumor cell line. Compromised DNA synthesis associated with interference with DNA unwinding may contribute to growth inhibition in MCF-7 cells exposed to doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8183243

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  94 in total

1.  Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins
Journal:  Cancer Biother Radiopharm       Date:  2011-08-11       Impact factor: 3.099

2.  Liposome-Cross-Linked Hybrid Hydrogels for Glutathione-Triggered Delivery of Multiple Cargo Molecules.

Authors:  Yingkai Liang; Kristi L Kiick
Journal:  Biomacromolecules       Date:  2016-01-25       Impact factor: 6.988

3.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

4.  Multiplex assay for condition-dependent changes in protein-protein interactions.

Authors:  Ulrich Schlecht; Molly Miranda; Sundari Suresh; Ronald W Davis; Robert P St Onge
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

Review 5.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

6.  Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.

Authors:  Aneta J Mieszawska; YongTae Kim; Anita Gianella; Inge van Rooy; Bram Priem; Matthew P Labarre; Canturk Ozcan; David P Cormode; Artiom Petrov; Robert Langer; Omid C Farokhzad; Zahi A Fayad; Willem J M Mulder
Journal:  Bioconjug Chem       Date:  2013-08-21       Impact factor: 4.774

7.  Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.

Authors:  Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

8.  Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.

Authors:  M Koutsilieris; C Reyes-Moreno; I Choki; A Sourla; C Doillon; N Pavlidis
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

9.  Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.

Authors:  Peter Bober; Michal Alexovic; Ivan Talian; Zuzana Tomkova; Zuzana Viscorova; Maria Benckova; Igor Andrasina; Rachele Ciccocioppo; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak; Jan Sabo
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

10.  Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.

Authors:  Laura E Strong; Shreyas N Dahotre; Jennifer L West
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.